Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...

Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Australia’s biggest payers have the biggest pay gaps. Nowhere is this more evident than in financial services, where the money men still dominate. Hopefully, employers will be able to use the ...

Press enter to select an edition. Use escape to exit selection.